Heterogeneity in Primary Colorectal Cancer and its Corresponding Metastases: A Potential Reason of EGFR-Targeted Therapy Failure?

被引：0
作者：
Li, Zhongqi [1 ]
Jin, Ketao [1 ,2 ]
Lan, Huanrong [3 ]
Teng, Lisong [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg Oncol, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Surg, Zhuji, Zhejiang, Peoples R China
[3] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Gynecol & Obstet, Zhuji, Zhejiang, Peoples R China
来源：
HEPATO-GASTROENTEROLOGY | 2011年 / 58卷 / 106期
关键词：
Colorectal cancer; Epidermal growth factor receptor; Heterogeneity; Targeted therapy; GROWTH-FACTOR-RECEPTOR; CETUXIMAB PLUS IRINOTECAN; PROGRESSION-FREE-SURVIVAL; K-RAS MUTATIONS; KRAS MUTATIONS; P53; MUTATIONS; INTRATUMOR HETEROGENEITY; PIK3CA MUTATIONS; PRIMARY TUMORS; HUMAN BREAST;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Epidermal growth factor receptor (EGFR)targeted therapy represents an important approach in metastatic colorectal cancer (CRC) therapy. However, a number of CRC patients show intrinsic or acquired resistance to EGFR-targeted therapy. EGFR antibody therapy is established in CRC patients with wild-type KRAS. However, up to half of these patients do not respond to this therapy. This phenomenon implied some potential mechanisms of resistance to EGFR inhibitors might exist. One of the potential reasons to explain this phenomenon is heterogeneity of CRC. The heterogeneity of CRC has been well described at the morphological, molecular and genomic levels. This review discussed the potential relationship of heterogeneity, including intratumor heterogeneity of CRC and heterogeneity in primary CRC and its corresponding metastases, to EGFR-targeted therapy failure.
引用
收藏
页码：411 / 416
页数：6
相关论文
共 50 条
  • [21] Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance
    Zhai, Zhenhua
    Yu, Xiaohui
    Yang, Bin
    Zhang, Yunjing
    Zhang, Long
    Li, Xiaoli
    Sun, Hongzhi
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2017, 64 : 107 - 115
  • [22] Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR-targeted therapy response in colorectal cancer
    Li, Weiwei
    Ma, Yiming
    He, Longmei
    Li, Hongwei
    Chu, Yi
    Jiang, Zheng
    Zhao, Xinhua
    Nie, Yongzhan
    Wang, Xishan
    Wang, Hongying
    CANCER LETTERS, 2021, 517 : 14 - 23
  • [23] EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
    Tulchinsky, Eugene
    Demidov, Oleg
    Kriajevska, Marina
    Barlev, Nickolai A.
    Imyanitov, Evgeny
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (01): : 29 - 39
  • [24] Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists
    Hoorens, A.
    Jouret-Mourin, A.
    Sempoux, C.
    Demetter, P.
    De Hertogh, G.
    Teugels, E.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2010, 73 (04): : 497 - 503
  • [25] Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients
    Riera, Pau
    Rodriguez-Santiago, Benjamin
    Lasa, Adriana
    Gonzalez-Quereda, Lidia
    Martin, Berta
    Salazar, Juliana
    Sebio, Ana
    Virgili, Anna C.
    Minguillon, Jordi
    Camps, Cristina
    Surralles, Jordi
    Paez, David
    CANCERS, 2020, 12 (08) : 1 - 15
  • [26] Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
    Misale, Sandra
    Di Nicolantonio, Federica
    Sartore-Bianchi, Andrea
    Siena, Salvatore
    Bardelli, Alberto
    CANCER DISCOVERY, 2014, 4 (11) : 1269 - 1280
  • [27] CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR-Targeted Therapy for Colorectal Cancer-From Concept to Practice
    Camp, E. Ramsay
    Ellis, Lee M.
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3578 - 3580
  • [28] Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
    Zhang, Zhenfeng
    Lee, Jae Cheol
    Lin, Luping
    Olivas, Victor
    Au, Valerie
    LaFramboise, Thomas
    Abdel-Rahman, Mohamed
    Wang, Xiaoqi
    Levine, Alan D.
    Rho, Jin Kyung
    Choi, Yun Jung
    Choi, Chang-Min
    Kim, Sang-We
    Jang, Se Jin
    Park, Young Soo
    Kim, Woo Sung
    Lee, Dae Ho
    Lee, Jung-Shin
    Miller, Vincent A.
    Arcila, Maria
    Ladanyi, Marc
    Moonsamy, Philicia
    Sawyers, Charles
    Boggon, Titus J.
    Ma, Patrick C.
    Costa, Carlota
    Taron, Miquel
    Rosell, Rafael
    Halmos, Balazs
    Bivona, Trever G.
    NATURE GENETICS, 2012, 44 (08) : 852 - +
  • [29] Development of EGFR-Targeted Nanoemulsion for Imaging and Novel Platinum Therapy of Ovarian Cancer
    Ganta, Srinivas
    Singh, Amit
    Patel, Niravkumar R.
    Cacaccio, Joseph
    Rawal, Yashesh H.
    Davis, Barbara J.
    Amiji, Mansoor M.
    Coleman, Timothy P.
    PHARMACEUTICAL RESEARCH, 2014, 31 (09) : 2490 - 2502
  • [30] Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
    Li, Qing-Hai
    Wang, Ying-Zhao
    Tu, Jian
    Liu, Chu-Wei
    Yuan, Yu-Jie
    Lin, Run
    He, Wei-Ling
    Cai, Shi-Rong
    He, Yu-Long
    Ye, Jin-Ning
    GASTROENTEROLOGY REPORT, 2020, 8 (03): : 179 - 191
12345